2 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
Follow ImmunoGenesis: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer TH-302 combination with pemetrexed, Matched placebo in combination with pemetrexed - Non-small Cell Lung Cancer | Phase 2 | Terminated | ImmunoGenesis | 265 | 2014-06-01 | 2025-05-16 |
| A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma TH-302 - Metastatic Melanoma | Phase 2 | Terminated | ImmunoGenesis | 11 | 2013-05-01 | 2025-05-11 |
Carcinoma, Non-Small-Cell Lung (1) · Lung Neoplasms (1) · Melanoma (1) · Neoplasm Metastasis (1)
Pemetrexed (1) · TH 302 (1)
United States (2) · Canada (1) · Czechia (1) · Germany (1) · Greece (1) · Hungary (1) · Italy (1) · Poland (1) · Romania (1) · Russia (1) · Spain (1)
Tillman Pearce, MD (2) · Jonathan Goldman, MD (1)